Research programme: PARP inhibitors - Eisai

Drug Profile

Research programme: PARP inhibitors - Eisai

Alternative Names: GPI 15427; GPI 18180; GPI 6000; Poly(ADP-ribose)-polymerase inhibitors research programme - MGI GP

Latest Information Update: 19 Feb 2010

Price : $50

At a glance

  • Originator MGI GP
  • Class Organic chemicals
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer
  • No development reported Hepatic fibrosis; Myocardial ischaemia; Stroke
  • Discontinued Alzheimer's disease; Brain injuries; Parkinson's disease; Rheumatoid arthritis; Septic shock; Type 1 diabetes mellitus

Most Recent Events

  • 19 Feb 2010 Preclinical development is ongoing in Cancer
  • 29 Jan 2008 Eisai acquires MGI PHARMA
  • 15 Feb 2007 GPI 21016 has been selected as the lead clinical candidate for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top